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Abstract
Histone variants are structural components of eukaryotic chromatin that can replace replication-
coupled histones in the nucleosome. The histone variant macroH2A.1.1 contains a macrodomain 
able to bind NAD+ derived metabolites. Here, we report that macroH2A.1.1 is rapidly induced 
during myogenic differentiation through a switch in alternative splicing. Importantly, myotubes 
lacking macroH2A.1.1 display a defect in mitochondrial respiratory capacity. We find that the 
metabolite-interacting macrodomain is essential for sustaining optimal mitochondrial function, but 
dispensable for gene regulation. Through direct binding, macroH2A.1.1 inhibits basal poly-ADP 
ribose polymerase 1 activity and thus reduces nuclear NAD+ consumption. Consequentially, 
accumulation of the NAD+ precursor NMN allows the maintenance of mitochondrial NAD+ pools 
critical for respiration.
Our data indicate that macroH2A.1.1-containing chromatin regulates mitochondrial respiration by 
limiting nuclear NAD+ consumption and establishing a buffer of NAD+ precursors in 
differentiated cells.
Introduction
NAD+ and its reduced and phosphorylated forms have central roles in cellular metabolism1. 
As donor and acceptor molecules for redox reactions they are essential for glycolysis and 
mitochondrial respiration2. In addition to redox metabolism, a number of enzymes consume 
NAD+ by breaking the energetic bond between its nicotinamide (NAM) and ADP ribose 
moiety. These enzymes include ADP ribose transferases, poly-ADP ribose (PAR) 
polymerases (PARPs), cADP ribose synthases and sirtuins1.
Of these enzymes PARP-1 is known to be the major NAD+ consuming enzyme in the cell3. 
PARP-1 is an abundant nuclear protein that functions in the cellular stress response. Best 
studied in the response to acute DNA damage, additional non-stress related functions, such 
as transcriptional regulation, have also been described4. Activated PARPs transfer ADP 
ribose to protein substrates and are able to generate elongated and branched PAR polymers5. 
Through their negative charge and capacity to recruit effector proteins PAR polymers are 
able to locally affect chromatin structure and function. Through the consumption of NAD+, 
PARP-1 is further linked to other NAD+-dependent reactions and energy metabolism6.
MacroH2A proteins are structural chromatin components that contribute to chromatin 
architecture7. As histone variants, they can replace the replication-coupled H2A histone in 
the structural unit of chromatin, the nucleosome. Among histone variants, macroH2A 
proteins are unique in having a tripartite structure consisting of a N-terminal histone fold, an 
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unstructured linker domain connecting a C-terminal macrodomain8. Macrodomains are 
ancient and globular folds that contain a binding pocket able to recognize NAD+ derived 
ADP ribose9. In evolution, macroH2A-encoding genes appeared at the transition to 
multicellular life10. In mammals, two genes and one mutually exclusive splicing event give 
rise to three macroH2A proteins – macroH2A1.1, macroH2A1.2 and macroH2A28. These 
three macroH2A proteins differ in the size and hydrophobicity of the binding pocket of their 
macrodomain. When a macroH2A protein is incorporated into chromatin, its unstructured 
linker domain places the macrodomain at an accessible site outside of the nucleosome11. 
Affinity for ADP ribose is limited to the splice variant macroH2A1.112. By binding ADP 
ribose in a capping mode, the macrodomain of macroH2A1.1 is further able to interact with 
PAR chains both when free or covalently linked to a protein13. The binding of 
macroH2A1.1 to auto-modified PARPs has been shown for several members of the PARP 
family including PARP-1/ARTD113,14, PARP-5/Tankyrase-1/ARTD515 and PARP-10/
ARTD1016,17.
Loss-of-function studies have demonstrated that macroH2A proteins contribute to the robust 
embryonic development in zebrafish18, are tumor suppressors in cancers such as 
melanoma19 and act as barriers to somatic cell reprogramming20. Mice lacking macroH2A-
encoding genes develop normally but display metabolic phenotypes, though controversy 
exists as to their role in metabolic fitness21–24. The first two studies reported glucose 
intolerance and female-specific liver steatosis21,22. However, when fed a high-fat diet, 
macroH2A1 knock-out mice were leaner due to higher energy expenditure and reduced fat 
mass23. To date, it remains entirely unclear whether the macrodomain and its ADP ribose 
binding capacity would be relevant for any of these phenotypes. Here, we have used a 
myogenic cell culture model to understand the role of macroH2A1.1 and its ADP ribose 
binding capacity on cellular metabolism.
Results
MacroH2A1 splicing switches during myogenesis
In order to identify the most suitable tissue and cell type to address the function of 
macroH2A1.1 and its metabolite binding capacity, we used restriction fragment length 
polymorphism to analyze the relative abundance of both alternatively spliced macroH2A1 
mRNAs in a panel of mouse tissues (Fig. 1a and Supplementary Fig. S1a,b). We detected the 
highest relative levels of macroH2A1.1 in skeletal muscle (Fig. 1a). When using an isoform-
specific antibody for immunoblotting25, macroH2A1.1 protein was readily detected in 
skeletal muscle (Fig. 1b). Next, we turned to cell culture of primary myoblast and immortal 
myogenic C2C12 cells. While both alternatively spliced mRNAs were detected in 
proliferating myoblasts, during myogenic differentiation the mRNA encoding macroH2A1.1 
rapidly became predominant (Fig. 1c,d and Supplementary Fig. S1c,d). On the protein level, 
macroH2A1.1 increased with differentiation in C2C12 cells as macroH2A1.2 decreased 
(Fig. 1e). Interestingly, the up regulation of macroH2A1.1 was much more pronounced on 
protein than RNA level (compare Fig.1d and e and Supplementary Fig. S1c and e). 
Comparison of macroH2A1.1 and macroH2A1.2 immunoblot signals in differentiated 
C2C12 cells to reference samples indicated that both protein isoforms were present at 
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comparable levels while macroH2A2 was much less abundant (Supplementary Fig. S1f). 
Not surprising for a chromatin component, we found that macroH2A1.1 is nuclear in muscle 
tissue and differentiating C2C12 cells (Supplementary Fig. S2a,b). To check that 
macroH2A1.1 is incorporated into chromatin, we confirmed its presence in the chromatin 
fraction after cellular fractionation (Supplementary Fig. S2c) and its genome-wide 
distribution in differentiated C2C12 cells by ChIP-seq (Supplementary Fig. S2d-f).
Taken together these results suggest that, compared to proliferating myoblasts, differentiated 
muscle nuclei are characterized by a chromatin state containing increased levels of 
macroH2A1.1, a histone variant isoform with the capacity to bind ADP ribose12. A switch 
in the alternative splicing of the macroH2A1 transcript provides a rapid way to establish this 
chromatin state during muscle differentiation.
Depletion of macroH2A1.1 induces metabolic changes but does not affect differentiation
Next, we decided to study the loss of function phenotype of macroH2A1.1 during myogenic 
differentiation of C2C12 cells. To specifically and efficiently suppress the expression of 
macroH2A1.1 and macroH2A1.2, we transfected proliferating C2C12 cells with isoform-
specific siRNAs and induced differentiation the day after transfection (see scheme in Fig. 
2a). Importantly, during 4 days of differentiation macroH2A1.1 and macroH2A1.2-depleted 
myoblasts were equally efficient as si control-treated cells to differentiate into 
multinucleated myotubes (Fig. 2b). While we did not observe any influence on the 
differentiation-induced upregulation of the key myogenic transcription factors MyoD and 
Myogenin, the expression of the late differentiation gene muscle-specific creatine kinase 
(Ckm) at day 4 of differentiation was slightly increased after knockdown of macroH2A1.1 
and reduced by knockdown of macroH2A1.2 (Fig. 2c). Together these results show that in 
contrast to the reported inhibition of myogenic differentiation by the stable suppression of 
total macroH2A126, the knockdown of individual macroH2A1 isoforms has only a minor 
influence on differentiation.
In order to understand the physiological relevance of macroH2A1.1 expression and its ADP 
ribose binding capacity in myotubes, we decided to focus our study on differentiated cells 
harvested at day 4 of differentiation. Intriguingly, knockdown of macroH2A1.1 led to 
reduced acidification of cell culture media (Fig. 2d). Analyzing the medium, we found that 
both glucose consumption and lactate production were reduced (Fig. 2e), indicating a global 
reduction of cellular metabolism in macroH2A1.1-depleted myotubes. To further explore 
this phenomenon, we measured rates of extracellular acidification and oxygen consumption 
as indirect read outs for glycolysis and oxidative phosphorylation. In keeping with reduced 
metabolic rates in macroH2A1.1-depleted myotubes, we found that these cells showed 
significantly reduced maximal glycolytic and mitochondrial capacities (Fig. 2f,g). Taken 
together these results suggest that specific reduction of macroH2A1.1 in the nucleus 
provokes a change in cellular metabolism that cannot be explained by a delay in 
differentiation.
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MacroH2A1.1 is required for optimal mitochondrial capacity
To characterize the nature of the alteration in mitochondrial metabolism, we decided to 
analyze the oxygen consumption rate in starved cells primed with fatty acids. As fatty acids 
represent direct mitochondrial substrates this allowed us to largely avoid confounding 
influences from cytosolic metabolic pathways. Under these conditions, macroH2A1.1 but 
not macroH2A1.2-depleted myotubes showed significantly impaired basal and maximal 
mitochondrial activity (Fig. 3a). The amount of mitochondrial DNA was not reduced by 
knockdown of macroH2A1.1 but rather showed a tendency to be increased (Fig. 3b). The 
expression of genes encoding components of the five complexes of the respiratory chain 
were induced during myogenic differentiation and in the case of the Cox4i1 gene slightly 
increased in macroH2A1.1-depleted myotubes (Fig. 3c). Further, we did not observe any 
changes in the ratio of nuclear and mitochondrially encoded respiratory chain transcripts 
(Fig. 3d), a finding that argued against any mito-nuclear protein imbalance as a possible 
cause of the defect27. Next, we tested whether the observed metabolic phenotype is 
mitochondria intrinsic or whether it may be caused by the cellular uptake of fatty acids. For 
this we have repeated the analysis of oxygen consumption rate after isolation of 
mitochondria from macroH2A1.1 depleted cells and found the results recapitulated; 
knockdown of macroH2A1.1 strongly reduced maximal mitochondrial capacity (Fig. 3e). 
Finally, we performed a gain-of-function experiment with immortal HepG2 cells expressing 
comparable amounts of macroH2A1.1 and macroH2A1.2 (Fig. 3f). To avoid any 
confounding influence of endogenous macroH2A isoform expression we have used 
previously described cells that were efficiently depleted for all macroH2A isoforms7. As 
shown in Fig. 3f, macroH2A1.1 but not macroH2A1.2 expression increased maximal 
respiratory capacity of these cells.
Together, these results suggest that the levels of macroH2A1.1 but not macroH2A1.2 
contribute to mitochondrial activity while leaving mitochondrial biogenesis unaffected.
Changes in gene expression are unlikely to account for the metabolic phenotype
As structural chromatin components macroH2A proteins have an ambivalent, most likely 
indirect role on gene expression and can affect transcription both positively and 
negatively28. In order to test whether changes in gene expression could explain the observed 
mitochondrial defect, we decided to perform a transcriptomic analysis comparing control 
and macroH2A1.1-depleted myotubes at day 4 of differentiation. This analysis allowed us to 
identify 797 differentially expressed genes (see Supplementary Data Set 2 for a complete 
list). Most of these changes were subtle and less than 50 genes were up- or down regulated 
more than two-fold (Supplementary Fig. S3a). Surprisingly, among these top regulated genes 
we did not identify any obvious candidates that could have explained the observed reduced 
metabolic activity (Fig. 4a). Rather contrarily, known fatty acid oxidation or glycolysis 
genes were not affected or slightly up regulated (Supplementary Fig. S3b). Furthermore, we 
did not find any enrichment of gene ontology terms related to metabolism in differentially 
expressed genes (Supplementary Data Set 2). Thus, the analysis of differentially expressed 
genes did not provide a testable hypothesis for the cause of the observed metabolic 
phenotype.
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To test whether integrity of the metabolite-binding pocket would be required for the 
influence of macroH2A1.1 on gene expression, we performed rescue experiments comparing 
wild-type macroH2A1.1 and the G224E mutant, that is unable to bind ADP ribose 12. 
Specifically, we stably overexpressed equal levels of both proteins in C2C12 cells that were 
depleted for endogenous macroH2A1.1 with siRNA and analyzed at day 4 of differentiation 
(Fig. 4b). We selected three top regulated genes (Itga11, Cdhr1 and Tmem171) and also 
included two genes related to muscle growth (Mstn and Igf1) in our analysis. We found that 
wild-type and mutant constructs were equally efficient in rescuing the transcription of all 
five genes (Fig.4c).
Taken together the capacity of macroH2A1.1 to regulate these genes in myotubes does not 
depend on ADP ribose binding.
MacroH2A1.1 binds and inhibits PARP-1
In contrast to gene regulation, the metabolic function of macroH2A1.1 depends at least in 
part on the integrity of its binding pocket. We used the same cells as for the transcriptional 
analysis (Fig. 4b,c) and compared wild-type and G224E mutant in a metabolic rescue 
experiment. While wild-type macroH2A1.1 was able to rescue maximal respiratory capacity, 
the G224E mutant was significantly less effective (Fig. 5a). This supports the idea that this 
function could be mediated by ADP ribose binding.
The binding pocket of the macroH2A1.1 macrodomain accommodates the ADP ribose 
molecule in a capping mode13. This allows macroH2A1.1 to bind ADP ribose also when 
part of a poly ADP ribose (PAR) chain or in the context of a post-translational modification 
covalently linked to protein, such as PARP-1. Since links to metabolic activity have been 
reported for PARP-129,30, we decided to confirm the binding of macroH2A1.1 to PARP-1 
and the requirement of the binding pocket in our setting. In vitro, we found that, when 
transfected into HEK293T cells, the macrodomain of wild-type macroH2A1.1, but not the 
G224E mutant or the macro domain of the macroH2A1.2 isoform, was able to precipitate 
PARylated PARP-1 (Fig. 5b). Next, we monitored the enzymatic capacity of recombinant 
PARP-1 in the presence of macrodomains. As shown in Fig. 5c, the wild-type macrodomain 
of macroH2A1.1 but not the G224E mutant inhibited the auto-PARylation of PARP-1. Next 
we moved to C2C12 cells and confirmed that also when expressed in cells the binding of 
macroH2A1.1 to PARP-1 depended on the integrity of its binding pocket (Fig. 5d). To test 
the influence of macroH2A1.1 on stress-induced PAR formation in cells, we have used 
quantitative immunofluorescence analysis of HepG2 cells expressing wild-type 
macroH2A1.1 or its binding pocket mutant G224E in a depleted background. After 
treatment with H2O2, PAR accumulates in the nucleus of the cells (Fig. 5e). This 
accumulation is largely inhibited when cells express wild-type macroH2A1.1, while 
expression of the G224E mutant had no affect.
In line with an earlier report31, macroH2A1.1 binds and inhibits PARP-1 in a manner that is 
dependent on the integrity of its ADP ribose-binding pocket.
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PARP inhibition rescues the mitochondrial phenotype
In continuation, we tested whether nuclear PARPs could be mediating the mitochondrial 
phenotype induced by macroH2A1.1 depletion. During myogenic differentiation PARP-1 
was down regulated on the level of mRNA and protein (Fig. 6a,b), while PARP-2 mRNA 
levels remained unaltered (Fig. 6a). In differentiated cells macroH2A1.1 and PARP-1 are 
expressed in a similar range but macroH2A1.1 is slightly more abundant than PARP-1 (Fig. 
6c). As we are lacking the tools to directly measure the basal activity of PARP-1, we decided 
to indirectly and rather globally assess cellular PARP activity by measuring the influence of 
a PARP inhibitor – specific for several PARPs including PARP-1 and PARP-2 – on the 
cellular levels of its enzymatic co-factor NAD+. We found that short-term treatment with the 
inhibitor increased the levels of NAD+ in proliferating myoblasts but not differentiated 
myotubes (Fig. 6d). These results suggest that PARPs could have a basal activity in 
myoblasts that is absent in myotubes.
To test our intriguing hypothesis that loss of PARP-1 inhibition by macroH2A1.1 depletion 
could mediate the described metabolic phenotype, we performed rescue experiments. 
Specifically, we treated differentiated C2C12 cells depleted for macroH2A1.1 with PARP 
inhibitor or co-transfected PARP-1 specific siRNA and determined mitochondrial capacity. 
As shown, both pharmacologic and genetic inhibition of PARP-1 was sufficient to rescue 
mitochondrial activity in macroH2A1.1-depleted myotubes and isolated mitochondria (Fig. 
6e and f).
Taken together these results further substantiate the idea that the influence of macroH2A1.1 
on mitochondrial activity is mediated by the inhibition of nuclear PARP activity, particularly 
of PARP-1.
The NAD+ precursor NMN mediates macroH2A1.1 influence on mitochondrial function
PARP-1 is one of the major consumers of the nuclear NAD+ pool3. To test whether changes 
in NAD+ metabolism could provide the molecular link between macroH2A1.1 and 
mitochondrial activity, we decided to assess possible changes in NAD+ and its precursors. 
The salvage pathway regenerating NAD+ from nicotinamide (NAM, see Fig. 7a) is the main 
biosynthetic pathway for NAD+1. After rate-limiting conversion of NAM to NAM 
mononucleotide (NMN) by nicotinamide phopshoribosyltransferase (Nampt) in the cytosol, 
different NMN adenyl transferases (Nmnat) generate NAD+ from NMN in different 
subcellular compartments32. During myogenic differentiation mRNAs encoding nuclear 
Nmnat1 and mitochondrial Nmnat3 were up regulated, while the mRNA of the Golgi/
cytosolic enzyme Nmnat2 was down regulated (Fig. 7b). Knockdown of macroH2A1.1 
increased the mRNA level of the Golgi enzyme but left those of nuclear and mitochondrial 
enzymes unaffected (Fig. 7b). Next, we directly measured the global cellular levels of NAD
+, NMN and NAM under the same conditions and found that knockdown of macroH2A1.1 
significantly reduced the level of NMN but left the other metabolites largely unaffected (Fig. 
7c). Interestingly, NMN was also the only metabolite of the NAD+ salvage pathway 
significantly changing during differentiation, being several-fold higher in differentiated cells 
(Fig. 7c). Next, we decided to test whether altered NMN levels would translate into a 
specific change in mitochondrial NAD+. For this we have purified mitochondria 
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(Supplementary Fig. S4a) and repeated the metabolite measurement. We found that both 
NMN and NAD+ were significantly reduced in mitochondria while the level of NAM was 
slightly increased (Fig. 7d). Thus, in myotubes lacking macroH2A1.1 the reduction of total 
and mitochondrial NMN correlated with reduced mitochondrial respiratory capacity. As 
shown in Figure 7e, addition of NMN to culture media was able to rescue mitochondrial 
respiratory capacity in macroH2A1.1-depleted cells. The same was true when mitochondria 
were isolated before analysis (Fig. 7f). Knockdown of the mitochondrial enzyme Nmnat-3 
reduced mitochondrial activity on its own and blunted the capacity of NMN to rescue 
mitochondrial respiration in macroH2A1.1-depleted cells (Fig. 7e and Supplementary Fig. 
S4b). Furthermore, neither NMN treatment nor PARP-1 inhibition rescued a panel of genes 
sensitive to macroH2A1.1 depletion (Supplementary Fig. S4c).
These results strongly support the idea that the influence of macroH2A1.1 on mitochondrial 
activity is mediated through NAD+ metabolism and in particular through the levels of the 
NAD+ precursor NMN (Fig. 7g).
To conclude, we have provided evidence that macroH2A1.1 controls mitochondrial 
metabolism in in a manner largely independent of gene regulation by maintaining proper 
mitochondrial levels of NAD+, through inhibiting its nuclear consumption by PARP-1.
Discussion
A structural chromatin component inhibits PARP-1 and affects mitochondrial activity
Our results describe a novel mechanism by which differentiating muscle cells couple a 
change in chromatin composition to de novo requirements for metabolic activity. Initially, 
we find that during myogenic differentiation muscle cells switch the splicing of the 
transcript encoding the histone variant macroH2A1 to an increased expression of ADP 
ribose-binding macroH2A1.1 isoform in myotubes. While myoblasts are highly proliferative 
and have a high demand for the generation of biomass, differentiating cells exit the cell cycle 
and shift towards increased use of carbon for mitochondrial ATP production. In our study, 
knockdown of macroH2A1.1 in myotubes reduced the oxidative capacity of their 
mitochondria, demonstrating that the knockdown of this structural chromatin component 
impacts cellular metabolism. Knockdown of the individual macroH2A1.1 splice isoform had 
no major influence on differentiation. Thus, the influence of macroH2A1.1 depletion on 
mitochondrial metabolism could not be explained by a simple delay in differentiation.
In the genome macroH2A1.1 is abundant and widely distributed making it suitable to 
mediate global nuclear effects. Taken together, our and previous results13,14,31 suggest that 
macroH2A1.1 can bind and inhibit auto-modified PARP-1 and possibly other nuclear 
PARPs. Basal PARP-1 activity is lost when its endogenous antagonist macroH2A1.1 
becomes expressed during myogenic differentiation. Although it is conceivable that strong 
stimuli will still be able to overcome this level of inhibition, the threshold for PARP-1 
activation is higher in fully differentiated cells that express macroH2A1.1. PARP-1 is the 
major NAD+ consuming activity in the nucleus3 and its activity impacts on NAD+ 
dependent reactions in other organelles and mitochondrial activity29,30. The expression of 
macroH2A1.1 and its dampening of PARP-1 activity might allow non-proliferating muscle 
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cells to avoid unnecessary, low stress-induced NAD+ consumption in the nucleus while 
prioritizing its use for ATP production in mitochondria and cell survival.
The influence on mitochondrial activity is largely independent of gene regulation
MacroH2A proteins have a reported ambivalent role in transcription28 that might be to some 
extent secondary to their function in regulating higher order chromatin architecture7. 
Although we cannot fully exclude a partial influence of gene regulation, several observations 
suggest that the influence of macroH2A1.1 on mitochondrial activity is largely independent 
of gene regulation. First, we did not identify any obvious candidate among the deregulated 
genes in macroH2A1.1-depleted myotubes. Second, PARP inhibition rescued the respiratory 
phenotype of macroH2A1.1-depleted cells (Figure 6e and f) while mimicking loss of 
macroH2A1.1 in gene regulation33. Third, in addition to PARP inhibition, also the addition 
of the NAD+ precursor NMN rescued the mitochondrial phenotype but not gene regulation 
(compare Fig.7e and Supplementary Fig. S4c). Finally, the experiments with the G224E 
mutant of macroH2A1.1 suggested that the binding pocket was required for rescuing 
respiratory capacity but not gene expression (compare Figures 4c and 5a). The requirement 
of ADP ribose capacity macroH2A1.1 is in line with the observation that macroH2A1.2 did 
not affect stress-induced PARylation or mitochondrial activity.
It is conceivable that all macroH2A proteins exert a common function in chromatin 
architecture and thus exert a shared influence on a subset of genes. The capacity to inhibit 
PARP-1 and possibly other PARPs, however, is unique for macroH2A1.1 and mediates its 
influence on mitochondrial activity.
NMN communicates metabolic states between nucleus and mitochondria
Nucleus and mitochondria are important organelles that control genome usage and energy 
metabolism, respectively. It is intuitive that cells have evolved mechanisms that allow them 
to communicate and coordinate these two key activities. As mitochondria and nuclei are 
spatially separated compartments, shared metabolites have great potential to act as 
messenger molecules. Our results suggest that changes in the level of the NAD+ precursor 
NMN mediate the influence of macroH2A1.1 on mitochondrial activity.
NAD+ is a key metabolite of the central metabolism and required for metabolic pathways in 
nucleus and mitochondria. NAD+ is indeed required for proper mitochondrial function, and 
its reduced form NADH is essential for the functioning of the respiratory chain2. As cells 
are known to be able to replenish NAD+ pools primarily through the salvage pathway 
regenerating NAD+ from NAM through NMN1, we also analyzed the influence of 
macroH2A1.1 depletion on the level of the precursors NMN and NAM. We found NMN to 
be depleted in macroH2A1.1 knockdown cells, suggesting that in the absence of 
macroH2A1.1, NAD+ consumption is indeed accelerated but largely compensated by the 
salvage pathway.
Since NAD+ cannot cross the mitochondrial membrane, mitochondrial and nucleo-
cytoplasmic NAD+ pools are separate. How mitochondria maintain their NAD+ pool is a 
topic of ongoing debate 34–37. A study using novel biosensors suggested that different 
mechanisms exist and that their relative contribution to the mitochondrial NAD+ pool is to 
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some extent cell-type dependent38. Among these mechanisms, the import of the precursor 
NMN and its subsequent conversion to NAD+ by Nmnat-3 contributes substantially to the 
mitochondrial NAD+ pool in several cell types37. We found that the depletion of total NMN 
pool in macroH2A1.1 knockdown cells resulted in a specific reduction of mitochondrial 
NAD+, while total NAD+ levels were not affected. This suggests that the mitochondria are 
less effective in regenerating NAD+ from NMN than the nucleo-cytosolic compartment. 
Indeed, the nuclear NNMAT1 has a lower Km for NMN than mitochondrial NMNAT332 
and thus might be more effective in regenerating NAD+, in particular when the concentration 
of NMN is decreased. Further, secondary biosynthetic pathways might facilitate the 
regeneration of NAD+ primarily in the cytosol. Independent of the exact mechanism, our 
results support a model in which NMN is in a central position communicating changes in 
nuclear NAD+ usage to mitochondria. In strong support of this model we find that addition 
of NMN to culture media is sufficient to rescue the mitochondrial defect in macroH2A1.1-
depleted cells (Fig. 7e,f). This rescue is abrogated by the knockdown of mitochondrial 
Nmnat3 confirming the necessity of the NMN salvage pathway for restoring normal 
mitochondrial activity.
In conclusion, our findings suggest a model in which the expression of macroH2A1.1 links 
the chromatin state to optimal energy metabolism through limiting nuclear NAD+ 
consumption and buffering of the NAD+ precursor NMN. Different mammalian tissues 
express different levels of macroH2A1.1 (Figure 1A), which provides a mechanism to adjust 
the threshold of nuclear PARP activation to cell-type specific nuclear and mitochondrial 
requirements for NAD+. Several studies have related the expression of macroH2A1.1 with 
the progression of differentiation and reduced proliferation39,40. It will be interesting to 
evaluate whether a shift in splicing towards more macroH2A1.1 might be a general 
phenomenon of terminal differentiation processes that are coupled to an exit from the cell 
cycle. The observation that overexpression of macroH2A1.1 but not macroH2A1.2 
prevented nutrient-enforced fat accumulation in liver cells41,42 supports the idea that such a 
mechanism would not be restricted to the muscle lineage. Future work will address the 
exciting question to what extent macroH2A1.1 controls metabolic homeostasis in vivo, 
particularly under conditions that challenge mitochondrial function such as stress, exercise 
and aging.
Online Methods
Cell cultures and isolation of primary myoblasts
C2C12 myoblasts (ATCC, CRL-1772) were grown in growth medium (GM) consisting of 
DMEM (Gibco) containing 20% FBS (Invitrogen) and 1% Penicillin-Streptomycin (Gibco). 
Tissues and primary mouse myoblasts were prepared from 2 month old C57BL/6 mice as 
described elsewhere43. Animal housing and handling procedures to isolate primay muscle 
cells were approved by the ethics committee of the Germans Trias i Pujol Research Institute, 
in accordance with the Catalan Government’s Animal Care guidelines. Primary myoblasts 
were maintained in Ham’s F10 (Gibco) medium complemented with 20% FBS (Invitrogen), 
10 ng/ml of bFGF (Invitrogen), 0,1% Fungizone (Invitrogen), Penicillin-Streptomycin. For 
primary myoblasts maintenance, cell culture plates were coated with rat-tail collagen I (BD 
Posavec Marjanović et al. Page 10













Biosciences) for 2h at 37ºC. For differentiation, cell culture plates were Matrigel-treated 
(BD Biosciences) for 1h at 37ºC. Differentiation medium (DM) for all cell cultures was 
DMEM supplemented with 2% Horse serum (Gibco) and Penicillin-Streptomycin. To induce 
differentiation, cells were seeded at high confluence and on the following day washed once 
with PBS before differentiation was induced by the addition of DM.
HEK293T (ATCC, CRL-3216), GP2 packaging cells (Clontech, 631458) and HepG2 
(HB-0865) were grown in DMEM containing 10% FBS and Penicillin-Streptomycin. 
Primary mouse myoblasts were prepared as described elsewhere43. Human primary 
myoblasts were kindly provided by Eduard Gallardo (Institut de Recerca Hospital de la 
Santa Creu i Sant Pau, Barcelona, Spain) and maintained in DMEM (Biowhittaker) 
containing 10% FBS (Hyclone), 15 ng/ml of bFGF (Invitrogen), 10 ng/ml EGF and 1% 
insulin 1 mg/ml (Sigma-Aldrich) and on 0,1% gelatin-coated plates. For differentiation, 
medium containing 1% insulin 1 mg/ml (Sigma-Aldrich) was used.
Plasmids, gene transduction and siRNA transfection
For plasmid construction, standard cloning techniques have been used. Mouse macroH2A1.1 
was amplified from C2C12 cell cDNA and inserted into a retroviral pBabe.puro backbone. 
The G224E pocket-binding mutant and the silent mutations at the siRNA recognition site 
were generated using Stratagene’s site-directed mutagenesis QuikChange protocol. Plasmids 
encoding GFP and His-tagged macro domains (corresponding to amino acids 155-369 of 
macroH2A1.1 and 155-372 of macroH2A1.2) were described previously13.
Retroviral infections were performed essentially as described with minor changes in the 
preparation of the target cells44. Briefly, C2C12 myoblasts were seeded the day prior to 
infection onto 6-well plates at the density of 10.000 cells per well. Cells were exposed to 
viral supernatant containing 0.3 volumes of fresh medium and 8 μg/ml polybrene (Sigma-
Aldrich) for 45 min while centrifugating at 1000 g and 32ºC and for another 1,5 h in the 
incubator.
Validated siRNAs45 were obtained from Invitrogen (see also Supplemental Information, 
Table S1) and transfected using OptiMEM (Gibco) and Lipofectamine RNAiMAX 
Transfection Reagent (Invitrogen) yielding a final concentration of 10 nM. For knockdown 
in myotubes, siRNA was repeatedly delivered at day -1, 0 and 2 of differentiation. HEK293T 
cells were transiently transfected using calcium-phosphate method as previously 
described46.
Antibodies and immunodetection
The following antibodies were used: anti-macroH2A1.125; anti-macroH2A1.2 (Cell 
Signalling, 4827S); anti-macroH2A1 and antimacroH2A218; anti-MyoD (Santa Cruz, 
sc-760), anti-eMHC F1.652 (Santa Cruz, sc-53091), anti-Myogenin F5D (Santa Cruz, 
sc-12732); anti-GFP (SantaCruz, sc-9996); anti-histone H3 (AbCam, ab-1791); anti-PARP-1 
(Abcam Ab6079, Trevigen 4338-MC-50); anti-NPM1 (Abcam), anti-PAR (AbCam 
ab14713, Trevigen 4336-APC-050), anti-Tubulin (Sigma-Aldrich, T6074), anti-NPM1 
(Abcam, ab10530), secondary anti-mouse and anti-rabbit conjugated to HRP 
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(DakoCytomation). The relative intensity of immunoblot bands was quantified by ImageJ 
software (version 2.0.0-rc-15/1.49k).
Immunoprecipitation and immunoblotting
For immunopreciptation, we have isolated nuclei and solubilized chromatin by sonication. 
Specifically, cells were collected by scraping and lysed in sucrose buffer (0.32M Sucrose,
10mM Tris HCl pH8.0, 3mM CaCl2, 2mM MgOAc, 0.1% Triton buffer, 1:100 PMSF and 
1:500 leupeptin). Samples were passed through a syringe to facilitate membrane disruption 
and further incubated for 8' on ice. Intact nuclei were collected by centrifugation for 3' at 
1000g and washed once more in sucrose buffer. Washed nuclei were resuspended in lysis 
buffer (50mM Tris HCl, pH7-8, 135mM NaCl, 0.1% Triton, 1mM EDTA, 1mM DTT, 1:100 
PMSF and 1:500 leupeptin) and chromatin was solubilized by progressive sonication using 
Bioruptor (Diagenode). For the precipitation of PARylated PARP-1, PARG and PARP 
inhibitors were added to the lysis buffer, 1 μM ADP-HPD (CalBioChem) and 1 μM Olaparib 
(SelleckChem), respectively. Remaining insoluble material was removed by centrifugation 
and lysates were pre-cleared using sepharose beads (Sigma). At this step, 5% of the total 
lysate was kept as input material and the rest of the lysate was incubated with antibody-
bound beads for 3 hours to over night. Beads were previously blocked with 1% BSA in lysis 
buffer. Precipitates were washed three times with lysis buffer containing 1% Triton X-100. 
For SDS-PAGE and Western blot analysis, typically 1% of input and 20% 
immunoprecipated material was loaded. The relative intensity of immunoblot bands was 
quantified by ImageJ software (version 2.0.0-rc-15/1.49k). For cell fractionations, nuclei 
were prepared as described above and the supernatant was kept as cytosolic fraction. Nuclei 
were then incubated with 410 mM KCl containing buffer (20mM HEPES pH 7.9, 1.5 mM 
MgCl2, 0.2 mM EDTA, 25% Glycerol, 1% NP-40) and ultracentrifugation was used to 
separate the chromatin (pellet) and nucleosol (supernatant).
Immunofluorescence and immunochemistry
For immunofluorescence, cells were grown on Menzel-Gläser slides and fixed in 4% 
paraformaldehyde (10 min at room temperature). The slides were permeabilizated for 10 
min with HCl 0,1M, 0.5% Triton-X 100 in PBS, and washed three times with PBST (PBS 
containing 0,1% Tween 20). Then, slides were pre-blocked with PBST-BSA (5%) for 30 min 
at room temperature, and incubated with a 1/50 to 1/100 dilution of specific primary 
antibody for 2 h in BSA 5% buffer. After three washes with PBST, the slides were incubated 
for 1h at room temperature with a 1/100 dilution of secondary goat anti-rabbit antibody 
conjugated to Alexa 488 (Thermo Fischer). After successive washes with PBST, slides were 
mounted with Vectashield® Mounting Medium with DAPI. Images were obtained using 
Leica DMI6000B Advance Fluorescence microscope (Leica) microscope equiped with a 
63x/1.4 Plan-Apochromat oil immersion objective. Images were loaded and analysed in Fiji, 
a distribution of ImageJ.
For immunohistochemistry, 10μM muscle sections were fixed in 100% cold acetone at room 
temperature. Immunostaining was performed incubating anti-macroH2A1.1 antibody for 1h 
in Ventana UltraView Universal DAB machine. Nuclei were additionally stained 1 min in 
Hematoxylin (Sigma-Aldrich). The sections were washed extensively, rinsed in 96% 
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ethanol, dehydrated twice in absolute ethanol and mounted. Frozen biopsy of human muscle 
was obtained from the Department for Pathologic Anatomy at the Hospital Universitari 
Germans Trias I Pujol (Badalona, Spain).
Bacterial protein expression and purification
BL21 (DE3) chemically competent E. coli were transformed with bacterial expression 
constructs and grown at 20°C after 500 μM IPTG induction. Bacteria were collected and 
lysed in lysis/wash buffer containing 50 mM Tris-HCl (pH 8), 300 mM NaCl, 10 mM 
imidazole and protease inhibitors. Afterwards, lysates were cleared by centrifugation for 30 
minutes at 4°C and 20000 g. The lysates were incubated with NTA-Ni beads (Quiagen) for 2 
h and washed with 10mM imidazole-containing buffer. Proteins of interest were 
subsequently eluted by 200mM imidazole-containing elution buffer. The eluted proteins 
were dialysed over-night against PBS, 5 mM β-mercaptoethanol and 10% glycogen, and 
finally stored at -80°C.
In vitro PARP-1 activity assay
Auto-PARylation was performed in the buffer containing 50 mM Tris-HCl (pH 8), 50 mM 
NaCl and 1 mM MgCl at room temperature for 20 minutes. Reaction volume of 30 μL 
contained 0,2 units/μL PARP-1 HSA enzyme (Trevigen), 0.3x activated DNA (from 10x 
activated DNA, Trevigen) and 200 μM NAD+ and different concentrations of purified 
macrodomains. Reactions were stopped by addition of Laemmli’s sample buffer and boiling 
on 95°C, separated on SDS-PAGE and analyzed by immunoblotting. Transferred proteins 
were counterstained with naphtol blue (Sigma).
RNA analysis including Restriction Fragment Length Polymorphism (RFLP)
Total RNA from cells was isolated using Invitrogen PureLink™ RNA kit and cDNA was 
synthesized using First strand cDNA synthesis kit (Fermentas) as described39. Relative 
cDNA levels were quantified by qRT-PCR. Values were normalized to two or three 
housekeeping genes (Rpo, GAPDH and Rpl7 for mouse samples; and HPRT1 and Rpo for 
human samples). All oligos were purchased from Invitrogen and are all listed in the 
Supplemental Information, Table S1. To check for the possible mitochondrial imbalance, 
two mitochondrially-encoded (ND3 and CoxI) and two nuclear genome encoded (Ndufa9, 
CoxIV) genes belonging to Complex I and IV were tested using TaqMan probes from 
Applied Biosystems (Life Technologies).
RFLP was used in order to qualitatively assess the amount of macroH2A1 isoforms. 
Essentially, cDNA obtained from RNA was used directly to perform the PCR reaction using 
oligos specifically annealing on exon 5 and exon 8 or exon 6 and 9 of the mouse and human 
H2afy/macroH2A1 transcripts, respectively. Amplicons were digested with HpaII/MspI 
restriction enzyme (ThermoScientific) for 2 h at 37ºC. See scheme in Figure S1b for further 
detail and Table S1 for oligo sequences. The digested products were separated by 2% 
agarose gel electrophoresis.
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All steps are performed at 4°C. Freshly collected cell pellets were resuspended in ice-cold 
hypotonic lysis buffer (10mM NaCl, 1,5mM MgCl2, 10mM Tris-HCl pH 7.5) containing 
deacetylases (10mM NAM, 2 μM TSA) and proteases inhibitors (1uM PMSF, 1uM 
Leupeptin) and incubated on ice for 2 min allowing swelling. To maintain the organelles 
intact, the ice-cold 2.5X homogenization buffer (800 mM Sucrose, 25 mM Tris HCl, 2,5 
mM EDTA) was added to the homogenate. Cell membranes were disrupted using 15 strokes 
of a teflon pestle in a Potter-Elvehjem homogeniser (Sigma-Aldrich). The nuclear fraction 
was removed by two successive centrifugations for 10 min at 1200 g. Mitochondria were 
collected by centrifugation for 20 min at 16000 g and resuspended in 1X homogenization 
buffer (320 mM Sucrose, 10 mM Tris HCl, 1 mM EDTA) containing protease and 
deacetylase inhibitors (10mM NAM, 2uM TSA, 1uM PMSF, 1uM Leupeptin).
Oxygen Consumption and Extracellular Acidification Rate Measurements
Analysis of oxygen consumption (OCR) and extracellular acidification (ECAR) rates was 
performed using a Seahorse XF96 Flux Analyzer (Seahorse Bioscience) as described 47. 
Briefly, 24 h post-siRNA transfection C2C12 cells were seeded onto XF 96-well cell culture 
microplates and the day after Mitochondrial Stress Test (MST) and Glycolytic Stress Test 
(GST) were performed. MST was performed in minimal medium containing 25 mM glucose 
subsequently adding 1 μM oligomycin, 3 μM FCCP and 2 μM Rotenone together with 2 μM 
Antimycin A. GST was performed in glucose-free medium adding 10 mM glucose and 10 
mM 2-deoxyglucose. For fatty acid oxidation MST, cells were additionally starved for 24 
hours in substrate-limited medium (DMEM containing 0,5 mM glucose, 1 mM glutamax, 
0,5 mM carnitine and 1% FBS) prior to the assay. Palmitate-BSA was added and MST 
performed. OCR and ECAR measurements were normalized for genomic DNA content.
Lactate and Glucose measurements
To measure lactate, cell culture supernatant was transferred to 5 mm NMR tubes. 1H-NMR 
spectra were recorded at 300 K on an Avance III 600 spectrometer (Bruker, Germany) 
operating at a proton frequency of 600.20 MHz using a 5 mm CPTCI triple resonance (1H, 
13C, 31P) gradient cryoprobe. One-dimensional 1H pulse experiments were carried out using 
the nuclear Overhauser effect spectroscopy (NOESY) presaturation sequence to suppress the 
residual water peak. The acquired spectral width was 12 kHz (20 ppm), and a total of 256 
transients were collected into 64 k data points for each 1H spectrum. 1H NMR spectra were 
referenced to the chemical shift of TSP signal at 0.0 ppm. References of pure compounds 
from the metabolic profiling AMIX spectra database (Bruker) and Chenomx database were 
used for lactic acid identification. After baseline correction, the specific NMR region of 
lactic acid was integrated using the AMIX 3.9 software package. Glucose concentrations 
were measured using glucose hexokinase method (Siemens, Dimension RHL Max Clinical 
Chemistry System, Siemens Healthcare Diagnostics) at the clinical biochemistry laboratory 
of the Hospital Universitari Germans Trias I Pujol (Spain).
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Adherent cells were washed 3 times with PBS, immediately collected by scraping and shock 
frozen. Alternatively, mitochondria were isolated and frozen as pellet. Metabolites were 
extracted into the extraction solvent by adding 300 μL of cold ACN/H2O (1:1). Samples 
were vigorously mixed by vortexing for 30 seconds and stored at –20 °C for 1 hour to enable 
protein precipitation. Subsequently, samples were centrifuged 15 minutes at 4 °C and 22600 
g and the supernatant was transferred to a LC-MS vial. The samples were analysed using an 
UHPLC system (1290 Agilent) coupled to a triple quadrupole (QqQ) MS (6490 Agilent 
Technologies) with iFunnel technology operated in multiple reaction monitoring (MRM) 
and positive electrospray ionization (ESI+) mode. Metabolites were separated using a C18-
RP (ACQUITY UPLC BEH 1.7 μm, Waters) chromatography at flow rate of 0.3 mL/min. 
The solvent system was A (20 mM ammonium acetate and 15 mM ammonia in 
water:acetonitrile [97:3]) and acetonitrile as B. The gradient elution started at 100% A (time 
0-1 min) and finished at 100% B (8-11 min). The injection volume was 5 ml. ESI conditions 
were: gas temperature, 170 °C; drying gas, 11 L/min; nebulizer, 20 psi; and fragmentor, 380 
V. Quality controls (QC) consisting of pooled samples were used. Four QC samples were 
injected repeatedly during the whole analysis. MRM transitions were: NAM (123.06→ 
107.10, 80.10), NMN (335.07→ 123.10, 97.00) and NAD+ (664.12→ 428.00, 136.00). The 
peak areas were manually integrated and the data normalized to total DNA for cells extracts 
and NDUFA9 protein for isolated mitochondria.
Transcriptomic Analysis
Cells were collected at day 4 of the differentiation, washed well with 1X PBS and stored as 
pellets at -80ºC. Experiment was repeated for more than 6 times. Once all the pellets were 
collected, RNA was extracted at once and aliquots of RNA were made. A small aliquot was 
used to transcribe the RNA into cDNA using the oligo(dT) (as described) and the knock-
down of macroH2A1.1 was tested in all biological replicates. Four biological replicates with 
most successful macroH2A1.1 knock-down were selected, RNA was quantified and quality 
was checked performing Eukaryote Total RNA Nano assay by IMPPC Genomics facility. 
RNA was amplified and loaded onto the microarray slide Agilent SurePrint G3 Mouse GE 
8x60K Microarray. Differentially expressed genes were identified with the LIMMA48 and 
selected with a cut-off of a q-value of 0,05 calculated after false discovery rate correction. 
The Gene Ontology analysis was performed using ChIPpeakAnno R package49 using p-
value < 0.01 and 30 for minGOterm (minimum count in a genome for a GO term to be 
included). A Bonferroni multiple hypothesis testing adjustment was finally applied to adjust 
the enrichment result. REVIGO online software was used to visualize summaries of the gene 
ontology analysis 50. Medium was chosen for the SimRel parameter.
ChIP-seq
We have used a described pan-macroH2A1 antibody18 for chromatin immunoprecipitation 
experiments coupled to massive parallel sequencing (ChIP-seq) that were performed and 
analysed essentially as previously with minor modifications. After cleaning and trimming, 
reads were aligned to mouse genome (mm9) using Bowtie 2 version 2.0.6, with sensitive 
pre-setting option (-D 15 -R 2 -L 22 -i S,1,1.15) 51. To detect genomic regions enriched for 
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multiple overlapping (peaks) SICER software version 1.1 was used to identify enriched 
genomic regions using the following settings: redundancy threshold= 2, window size=600, 
fragment size=250, effective genome fraction = 0.75, gap=1200, FDR=0.05 52.
Statistical Analysis
If not indicated otherwise, data is represented as mean of three or more biological replicates 
± standard deviation. If not indicated otherwise, two-tailed student t-test was used to assess 
statistical significance. The number of biological replicates or independent cell culture 
experiments is indicated in the figure legends. A Life Sciences Reporting Summary for this 
article is available online.
Data Access
Microarray expression and ChIP-seq data has been deposited in GEO, with and is available 
under accession number GSE78257.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. A splicing switch up regulates macroH2A1.1 during myogenic differentiation.
(a) Restriction fragment length polymorphism (RFLP) of macroH2A1 (mH2A1)-encoding 
transcripts in a panel of mouse tissues. Fragments sizes were 131 bp for macroH2A1.1 and 
two overlapping fragments of 89 bp for macroH2A1.2 (see also Supplementary Fig. S1a and 
b for more detail).
(b) Immunoblot analysis of mouse skeletal muscle and FLAG-tagged reference samples 
using isoform-specific macroH2A1.1 antibody and anti-FLAG.
(c) Primary myoblasts and C2C12 cells were differentiated (DM, differentiation medium) 
and analyzed by RFLP. Please note that resulting fragment sizes are different in human and 
mouse samples (see Supplementary Fig. S1b). (c)-(e) The zero time point refers to 
subconfluent cells grown in growth medium.
(d) Relative mRNA levels of macroH2A transcripts (normalized to equimolar reference 
samples to allow direct comparison) and differentiation markers Myogenin (Myog) and 
muscle-specific creatine kinase (Ckm) during a time course of differentiation were analyzed 
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by RT-qPCR. Data is presented as mean + s.d. (n = 3 independent experiments; *p<0.05 
compared to control at same time point).
(e) Immunoblot analysis of C2C12 cells during a time course of differentiation. MacroH2A1 
isoforms, histone H3 and the differentiation markers MyoG and embryonic myosin heavy 
chain (eMHC) were analyzed.
(a-c and e) Uncropped gel and blot images are shown in Supplementary Data Set 1.
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Figure 2. Knockdown of macroH2A1.1 results in metabolic changes, but does not affect myogenic 
differentiation.
(a) Scheme of the experimental set up. Proliferating C2C12 cells were first grown in growth 
medium (GM) and differentiated in differentiation medium (DM). Medium changes and 
siRNA transfections are indicated. mRNA levels were analyzed by RT-qPCR. Data is mean 
+ s.d. (n = 5 independent experiments; * = p<0,05 comparing to si Ctrl).
(b) C2C12 cells were treated as described in (a) and analyzed at day 4 (DM) using anti-
embryonic myosin heavy chain immunostaining (green) as marker of myotubes and DAPI as 
DNA counterstain (blue). Column graphs show the total number of nuclei that were 
analyzed in a predefined area and as measure of differentiation the percentage number of 
nuclei in eMHC-stained cells (n = 3 independent experiments; ns, not significant).
(c) Relative RNA levels of differentiation genes MyoD, myogenin (MyoG), and muscle-
specific creatine kinase (Ckm) analyzed by RT-qPCR (n = 4 independent experiments, * = 
p<0,05 comparing to si Ctrl).
(d) Differences in medium color observed after 4 days of differentiation and 48 hours after 
last media change.
(e) Extracellular glucose (n = 3) and lactate (n = 4) levels and total cellular protein 
concentration (n = 4) were measured in samples shown in (d). Data is represented as mean + 
s.d. of n independent experiments (*p<0,05; ns, not significant).
Posavec Marjanović et al. Page 21













(f) Glycolysis was analyzed by monitoring extracellular acidification rate (ECAR) in 
siRNA-treated C2C12 cells after overnight glucose starvation (n = 5 independent 
experiments), Glucose (Glc) addition and quenching with 2-deoxyglucose (2-DG), 
normalized for genomic DNA content.
(g) Mitochondrial respiratory capacity was assessed by measuring oxygen consumption rate 
(OCR) of siRNA-transfected C2C12 cells in medium with normal sugar content normalized 
for genomic DNA content (n = 5 independent experiments). As indicated the ATPase 
inhibitor oligomycin (O), the uncoupling compound FCCP (F) and the electron transport 
chain inhibitors Rotenone/Antimycin A (AA) were subsequently added.
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Figure 3. Knockdown of macroH2A1.1 causes defective mitochondrial respiration.
(a) Starved C2C12 cells were primed with fatty acids and ATPase inhibitor oligomycin (O), 
the uncoupling compound FCCP (F) and the electron transport chain inhibitors Rotenone/
Antimycin A (AA) were subsequently added. C2C12 cells were previously treated with si 
control (si Ctrl), si macroH2A1.1 and si macroH2A1.2 (si mH2A1.1/1.2). On the right, the 
relative maximal respiration is blotted (mean + s.d., n = 6 independent experiments; 
*p<0,05).
(b) Mitochondrial DNA content normalized to nuclear DNA using the ND2 and Ndufv1 
gene, respectively (mean + s.d., n = 6 independent experiments).
(c) RT-qPCR analysis of mRNAs encoding components of respiratory chain complexes in 
proliferating (GM) and differentiated cells (DM, 4 days) treated with si macroH2A1.1 or si 
Ctrl (Data is mean + s.d.; si Ctrl set to 1; n = 4 independent experiments; *p<0.05).
(d) The mRNA levels of nuclear and mitochondrial genes encoding components of complex 
I (Ndufa9 and ND3) and IV (CoxIV and CoxI) were measured by Taqman probed RT-qPCR 
to assess balanced transcription. Data is represented as mean + s.d. of 4 independent 
experiments.
(e) Same conditions as in (a), but mitochondria were isolated prior to the analysis of 
respiration from si Ctrl and si mH2A1.1-treated cells (mean + s.d.; n = 6 independent 
experiments; *p<0,05).
(f) Fatty acid oxidation assay of HepG2 cells double knock-down for macroH2A1 and 
macroH2A2 (DKD) stably expressing transgenic FLAG-tagged macroH2A1.1, 
macroH2A1.2 or none of both (control). Data is mean + s.d. of 9 measurements of different 
cultures (*p<0,05). On the right immunoblots with indicated antibodies show the expression 
levels. Lanes 3 and 4 are samples of DKD cells expressing YFP-tagged wild-type and 
G224E mutant macroH2A1.1, respectively (further analyzed in Fig. 5e). Uncropped blot 
images are shown in Supplementary Data Set 1.
Posavec Marjanović et al. Page 23













Figure 4. Gene regulation by macroH2A1.1 is independent of ADP ribose binding.
(a) Heatmap of top differentially expressed genes (fold change ≥ 2, *p<0.05) in si 
macroH2A1.1 (mH2A1.1) to si ctrl C2C12 cells after 4 days of differentiation. For a full list 
of all differentially expressed genes please see Supplementary Data Set 2.
(b) FLAG-epitope tagged wild-type and G224E mutant macroH2A1.1 (e-mH2A1.1) were 
stably expressed in C2C12 cells depleted for endogenous macroH2A1.1 with siRNA. The 
resulting expression levels were analyzed in C2C12 myotubes after 4 days of differentiation 
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by immunoblotting using anti-FLAG and anti-macroH2A1.1 antibodies. H3 was used as 
loading control.
(c) A panel of 5 differentially expressed genes were analyzed in the same myotube samples 
shown in (b) by RT-qPCR (n=3 independent siRNA transfection experiments using the same 
stable cell lines; *p<0,05).
Posavec Marjanović et al. Page 25













Figure 5. The binding pocket of macroH2A1.1 is required for mitochondrial activity, binding of 
PARP-1 and its inhibition.
(a) Maximal mitochondrial capacity of cells expressing epitope tagged wild-type (WT) and 
G224E mutant macroH2A1.1 (mH2A1.1) and transfected with macroH2A1.1 siRNA was 
assessed by measuring the oxygen consumption rate (OCR) as in Figure 3a using the same 
cells as shown in Figure 4c and d. Data is represented as mean + s.d. relative to si Ctrl-
treated cells set to 1 (n = 6 independent experiments; *p<0,05).
(b) Immunoblots of input and anti-GFP immunoprecipitates (IP) from transfected HEK293T 
cells expressing fusion proteins of GFP and macrodomains using indicated antibodies.
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(c) PARP-1 activity was assessed by its in vitro auto-PARylation capacity in the presence of 
increasing concentrations (1, 10, 25 and 50 μM) of His-tagged mH2A1.1 WT and G224E 
mutant macrodomain followed by anti-PAR immunoblotting and naphtol blue staining.
(d) FLAG-tagged wild-type (WT) and G224E mutant macroH2A1.1 were expressed in 
C2C12 cells. Anti-FLAG immunoprecipitates (IP) were analyzed by immunoblotting using 
indicated antibodies.
(e) HepG2 cells double knock-down for macroH2A1 and macroH2A2 (DKD) expressing 
exogenous YFP-tagged WT and G224E mutant macroH2A1.1 were H2O2 treated (0.1 mM, 
10 min) and analyzed by anti-PAR immunostaining (shown in color scale), YFP 
autofluorescence and DAPI counterstaining. The boxplot on the right shows quantification 
the mean nuclear PAR signal in arbitrary units (AU). Each dot represents the measurement 
of an individual cell (*p<0,05, Wilcoxon test). The box represents the 25-75th percentiles, 
and the median is indicated with a bar. The whiskers show the highest and lowest data point 
within the 1.5 IQR of the upper and lower quartile, respectively. Overall expression levels of 
WT and G224E mutant protein are shown in Figure 3f, lanes 3 and 4, respectively.
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Figure 6. Inhibition of PARP-1 rescues the mitochondrial phenotype.
(a) Nuclear PARPs are expressed in differentiated myotubes. mRNA levels of PARP-1 and 
PARP-2 were analyzed in proliferating myoblasts in growth medium (GM) and 
differentiated myotubes after 4 days in differentiation medium (DM). Data is presented as 
mean + s.d. of 4 independent differentiation experiments (*p<0.05).
(b) Western blot with the indicated antibodies of C2C12 cells grown under the same 
conditions as in (a).
(c) Comparison of the Western blot signal of PARP-1 and macroH2A1.1 in differentiated 
C2C12 cells (DM) to equal amounts of purified reference proteins. Full-length PARP-1 and 
His-tagged macroH2A1.1 macro domain was used. Uncropped blot images of (b) and (c) are 
shown in Supplementary Data Set 1.
(d) The NAD+ levels in myoblasts but not myotubes are sensitive to PARP inhibition. 
Proliferating (GM) and differentiated C2C12 cells (DM) were treated with 100 nM PARP 
inhibitor ABT-888. Data is presented as mean + s.d. of 4 independent experiments (untreated 
set to 1; *p<0.05).
(g) Rescue of mitochondrial activity by genetic and pharmacologic PARP inhibition. 
Maximal respiratory capacity in fatty acid primed C2C12 cells treated with siRNA for 4 
days and was rescued by co-administration of 100 nM PARP inhibitor ABT-888 for 16 hours 
(left panel) or co-transfection of PARP-1 siRNA (right panel). Data is mean + s.d. (n=6 
independent experiments; *p<0.05) and si Ctrl cells treated or not with DMSO vehicle (left 
and right panel, respectively) were set to 100%.
(h) Same conditions as in (g) but mitochondria were isolated prior to the analysis of 
respiration.
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Figure 7. The influence of macroH2A1.1 on mitochondrial function is mediated by the NAD+ 
precursor NMN.
(a) Schematic representation of the NAD+ salvage pathway and its reported 
compartmentalization.
(b) The level of mRNA encoding the enzymes of the NAD+ salvage pathway was analyzed 
by RT-qPCR in proliferating (GM) and differentiated C2C12 cells (DM, day 4) treated with 
si macroH2A1.1 or control. Data is mean + s.d and mRNA levels in differentiated control 
cells were set to 1 (n=4 independent experiments; * = p<0,05). The reported main 
localization of the encoded enzymes is indicated.
(c) Quantification of the metabolites of the NAD+-salvage pathway by LC-MS/MS in 
proliferating (GM) and differentiated C2C12 cells (DM, day 4) treated with or without si 
macroH2A1.1. Data is mean + s.d. of 4 independent experiments (*p<0.05).
(d) Quantification of the metabolites mitochondria isolated from C2C12 myotubes at 4 day 
of differentiation treated with si macroH2A1.1 or control si RNA (Ctrl). Data was 
normalized for mitochondrial NDUFA9 protein levels and is represented as mean + s.d. of 4 
independent experiments (* = p<0,05).
(e) NMN rescues mitochondrial capacity. Using fatty acid oxidation assay, the maximal 
respiratory capacity in fatty acid primed C2C12 cells treated with siRNAs and 500 nM 
NMN for 24 hours was analyzed at day 4 of differentiation. Data is represented as mean + 
s.d. of 6 independent experiments (*p<0.05).
(f) Same conditions as in (e) but mitochondria were isolated prior to the analysis of 
respiration.
(g) Schematic summary of our results showing how NMN links nuclear PARP-1 inhibition 
by macroH2A1.1 to the maintenance of the mitochondrial NAD+ pool.
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